Clinical trial NCT06122714: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
Official title: A Phase I Randomised, Single-blind, Placebo-controlled, and Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Participants
Keywords: Single ascending dose (SAD)
Multiple ascending dose (MAD)
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Parexel
First posted: 2023-11-08
Enrollment: 95
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4144 administered orally in healthy participants.

Detailed description: This is a Phase I, first time-in human (FTiH), randomised, single-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) sequential group study in healthy participants.

Part A consists of 3 parts:

Part A1 (healthy participants) Part A2 (healthy Japanese participants) and Part A3 (healthy Chinese participants)

Part B consists of 2 parts:

Part B1 (healthy participants) Part B2 (healthy Japanese participants)

Both Part A and Part B of the study will comprise of a screening period of maximum 28 days. The treatment period would last from Day -1 to Day 4 in Part A and from Day -1 to Day 15 in Part B of the study. A follow up visit will be performed on Day 10 + 3 days for Part A and on Day 20 + 3 days for Part B.

Each participant will participate for about 6 weeks in Part A of the study and for about 7 weeks in Part B of the study.

Eligibility criteria: Inclusion criteria:

* Females must have a negative pregnancy test, must not be lactating and must be of non-childbearing potential.
* Have a BMI between 18 and 32 kg/m2 inclusive at both Screening and Admission and weigh at least 45 kg at Screening.
* For healthy Japanese cohorts (Part A2 and Part B2): healthy male and female (of non-childbearing potential) participants are to be Japanese, defined as having both parents and four grandparents who are Japanese. This included second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.
* For healthy Chinese cohort (Part A3): healthy male and female (of non-childbearing potential) Chinese participants for whom both parents and all grandparents are Chinese and not lived outside of China for more than 10 years.

Exclusion criteria:

* History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study.
* History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
* Any clinically important illness, medical/surgical procedure or trauma.
* Clinically significant serious active and chronic infections.
* Bacillus Calmette-Guérin vaccine within one year prior to signing the ICF.
* Any abnormal laboratory values at the Screening Visit.
* Any positive result on Screening for serum Hepatitis B surface antigen (HBsAg), anti-Hepatitis B core (HBc), hepatitis C antibody, or Human Immunodeficiency Virus (HIV).
* Any cardiac abnormalities.
* History of alcohol abuse or drug abuse.
* Current smokers or those who have smoked or used nicotine products.
* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity.
* Clinical signs and symptoms consistent with COVID-19.
* In addition, any of the following is regarded as a criterion for exclusion from the genetic research:

  1. Previous bone marrow transplant
  2. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection

Primary outcomes:
measure: Number of participants with adverse events (AEs)
timeFrame: Part A: From screening (Day -28 to Day -2) to Day 10; Part B: From screening (Day -28 to Day-2) to Day 20
Secondary outcomes:
measure: Maximum observed plasma (peak) drug concentration (Cmax)
timeFrame: Part A: Day 1 to Day 4. and Day 10; Part B: Day 1 to Day 15 and Day 20
measure: Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)
timeFrame: Part A: Day 1 to Day 4. and Day 10; Part B: Day 1 to Day 15 and Day 20
measure: Area under plasma concentration-time curve from zero to infinity (AUC0-inf)
timeFrame: Part A: Day 1 to Day 4. and Day 10; Part B: Day 1 to Day 15 and Day 20
measure: Renal clearance of drug from plasma (CLR)
timeFrame: Part A: Day 1 to Day 4. and Day 10; Part B: Day 1 to Day 15 and Day 20
measure: PD analysis: Levels of disease-specific biomarkers
timeFrame: Part A: Day 1 to Day 4 and Day 10; Part B: Day -1, Day 1 to Day 4, Day 12 to Day 15 and Day 20
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Research Site
state: California
city: Brooklyn
country: United States
facility: Research Site
state: Maryland
Study officials:
References: